Provided by Tiger Trade Technology Pte. Ltd.

Reviva Pharmaceuticals Holdings, Inc.

0.8799
+0.00941.08%
Post-market: 0.90000.0201+2.28%19:17 EDT
Volume:202.70K
Turnover:176.99K
Market Cap:11.20M
PE:-0.16
High:0.9104
Open:0.8705
Low:0.8543
Close:0.8705
52wk High:23.20
52wk Low:0.5900
Shares:12.73M
Float Shares:12.55M
Volume Ratio:0.81
T/O Rate:1.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.4800
EPS(LYR):-18.0520
ROE:-419.97%
ROA:-80.35%
PB:1.29
PE(LYR):-0.05

Loading ...

Reviva CEO to join A.G.P. fireside chat on brilaroxazine milestones

Reuters
·
Apr 23

Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications

GlobeNewswire
·
Apr 23

Reviva Pharmaceuticals Holdings - to Initiate Trial Activities in Q2 2026 , Begin Enrollment in Q3 2026, for Recover-2 - SEC Filing

THOMSON REUTERS
·
Apr 15

Reviva Pharmaceuticals Holdings Inc - Aims to Extend Brilaroxazine Patent Life and Exclusivity Potentially Through 2046 - SEC Filing

THOMSON REUTERS
·
Apr 15

Reviva Pharmaceuticals issues shareholder letter for past year in earnings release

Reuters
·
Apr 15

Reviva Announces Letter to Shareholders

GlobeNewswire
·
Apr 15

Reviva Pharm Holdings Cut to Hold From Buy by Maxim Group

Dow Jones
·
Apr 08

Reviva Pharmaceuticals downgraded to Hold from Buy at Maxim

TIPRANKS
·
Apr 08

Reviva Pharmaceuticals Holdings Inc : Maxim Group Cuts to Hold From Buy

THOMSON REUTERS
·
Apr 08

Reviva Pharmaceuticals Holdings (RVPH) Gets a Buy from Roth MKM

TIPRANKS
·
Apr 01

BRIEF-Reviva Reports Full Year 2025 Financial Results And Recent Business Highlights

Reuters
·
Mar 30

Reviva Pharmaceuticals Q4 EPS $(0.57) Misses $(0.10) Estimate

Benzinga
·
Mar 30

Reviva Pharmaceuticals' 2025 net loss narrows on lower R&D spending

Reuters
·
Mar 30

Reviva FY25 net loss narrows 33.61% to $19.9 million

Reuters
·
Mar 30

Press Release: Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights

Dow Jones
·
Mar 30

Reviva Pharmaceuticals Holdings Inc expected to post a loss of $1.17 a share - Earnings Preview

Reuters
·
Mar 27

Reviva Pharmaceuticals closes USD 10 million public offering of common stock and warrants

Reuters
·
Mar 23

Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering

GlobeNewswire
·
Mar 23

Gold Tumbles Over 6%; Accenture Earnings Top Views

Benzinga
·
Mar 20

BUZZ-U.S. STOCKS ON THE MOVE-Rivian,  Biohaven, CervoMed

Reuters
·
Mar 19